Glucopyranosyl lipid A - Immune Design

Drug Profile

Glucopyranosyl lipid A - Immune Design

Alternative Names: G 100; GLA; GLA-SE; Glucopyranosyl lipid adjuvant - Immune Design; ID-G100

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immune Design
  • Developer Immune Design; Merck & Co
  • Class Adjuvants; Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Immunostimulants; Toll-like receptor 4 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-Hodgkin's lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-Hodgkin's lymphoma
  • Phase I Merkel cell carcinoma; Soft tissue sarcoma

Most Recent Events

  • 05 Jun 2017 Adverse events, efficacy, immunogenicity data from a phase I/II trial for Non-Hodgkin's lymphoma presented at the Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 30 May 2017 Immune Design completes enrolment in its phase I trial for Soft tissue sarcoma (Late-stage disease, Metastatic disease, Combination therapy) in USA
  • 18 May 2017 Efficacy data from a clinical trial in Non-Hodgkin's lymphoma released by Immune Design
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top